Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Import Two-fer: Consolidated Hearings Could Speed Counterfeit Destruction

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed rule aims to deter bad actors looking to introduce the products into the U.S. drug supply.

You may also be interested in...



FDA Secure Supply Chain Pilot Draws Small Group, But Could Serve Globalization Goals

Agency planned for up to 100 participants in program allowing expedited entry of some imports, but only approved 13.

FDA To Close Office In Amman, Jordan; Operations Moving To White Oak

Opened as part of the globalization initiative, FDA’s presence in the Middle East and North Africa will shut down in late December in an apparent cost-cutting effort.

FDA Counterfeit Screening Tool Gets Field Test In Ghana; Corning Prepares Device For Mass Production

FDA currently employs the CD3 in its laboratories and at a number of international mail facilities and other points of entry to the U.S. to screen cosmetics, foods, medical devices and cigarettes, as well as drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS077280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel